Primary high-risk HPV screening for cervical cancer in post-menopausal women

Gynecologic Oncology

Volumn 125, Issue 2, 2012, Pages 343-345

  Gyllensten, Ulf ^a,b   Gustavsson, Inger ^a,b   Lindell, Monica ^a,b   Wilander, Erik ^a,b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cervix; CIN; High risk HPV; Post menopausal; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER SCREENING; DIAGNOSTIC VALUE; FEMALE; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; POSTMENOPAUSE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

AGED; ALPHAPAPILLOMAVIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; COHORT STUDIES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POSTMENOPAUSE; REAL-TIME POLYMERASE CHAIN REACTION; SWEDEN; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84859591202     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2012.01.036     Document Type: Article

References (26)

1. Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999;81:159-66. (Pubitemid 29415507)
2. Epidemiology TboHaWCf. Cancer incidence in Sweden; 2009.
3. Gustafsson L, Sparen P, Gustafsson M, Pettersson B, Wilander E, Bergstrom R, et al. Low efficiency of cytologic screening for cancer in situ of the cervix in older women. Int J Cancer 1995;63:804-9.
4. Gyllensten U, Lindell M, Gustafsson I, Wilander E. HPV test shows low sensitivity of Pap screen in older women. Lancet Oncol 2010;11:509-10 author reply 510-1.
5. Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla Palma P, Del Mistro A, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol 2010;11:249-57.
6. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 2007;195:1582-9. (Pubitemid 46799215)
7. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907. (Pubitemid 47371147)
8. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 2008;100:513-7.
9. Castle PE, Rodriguez AC, Burk RD, Herrero R, Wacholder S, Alfaro M, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ 2009;339:b2569.
10. Wright Jr TC, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
11. Cuschieri KS, Cubie HA. The role of human papillomavirus testing in cervical screening. J Clin Virol 2005;32(Suppl. 1):S34-42. (Pubitemid 40332587)
12. Meijer CJ, Berkhof J, Castle PE, Hesselink AT, Franco EL, Ronco G, et al. Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer 2009;124:516-20.
13. Jacobs MV, Walboomers JM, Snijders PJ, Voorhorst FJ, Verheijen RH, Fransen- Daalmeijer N, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000;87:221-7. (Pubitemid 30434349)
14. Wikstrom I, Stenvall H, Wilander E. Low prevalence of high-risk HPV in older women not attending organized cytological screening: a pilot study. Acta Derm Venereol 2007;87:554-5. (Pubitemid 351373409)
15. Sanner K, Wikstrom I, Strand A, Lindell M, Wilander E. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing. Br J Cancer 2009;101: 871-4.
16. Gustavsson I, Juko-Pecirep I, Backlund I, Wilander E, Gyllensten U. Comparison between the Hybrid Capture 2 and the hpVIR real-time PCR for detection of human papillomavirus in women with ASCUS or low grade dysplasia. J Clin Virol 2009;45:85-9.
17. Gustavsson I, Lindell M, Wilander E, Strand A, Gyllensten U. Use of FTA card for dry collection, transportation and storage of cervical cell specimen to detect high-risk HPV. J Clin Virol 2009;46:112-6.
18. Gustavsson I, Sanner K, Lindell M, Strand A, Olovsson M, Wikstrom I, et al. Typespecific detection of high-risk human papillomavirus (HPV) in self-sampled cervicovaginal cells applied to FTA elute cartridge. J Clin Virol 2011;51:255-8.
19. Gyllensten U, Sanner K, Gustavsson I, Lindell M, Wikstrom I, Wilander E. Shorttime repeat high-risk HPV testing by self-sampling for screening of cervical cancer. Br J Cancer 2011;105:694-7.
20. Dillner J, Rebolj M, Birembaut P, Petry KU, Szarewski A, Munk C, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
21. Naucler P, Ryd W, Tornberg S, Strand A, Wadell G, Elfgren K, et al. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. J Natl Cancer Inst 2009;101:88-99.
22. Rijkaart DC, Berkhof J, van Kemenade FJ, Coupe VM, Hesselink AT, Rozendaal L, et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2011, doi:10.1002/ijc.26056 [Epub ahead of print].
23. Menezes GA, Wakely Jr PE, Stripe DM, Nuovo GJ. Increased incidence of atypical Papanicolaou tests from ThinPreps of postmenopausal women receiving hormone replacement therapy. Cancer 2001;93:357-63. (Pubitemid 34019636)
24. Feng J, Al-Abbadi MA, Bandyopadhyay S, Salimnia H, Husain M. Significance of high-risk human papillomavirus DNA-positive atypical squamous cells of undetermined significance pap smears in perimenopausal and postmenopausal women. Acta Cytol 2008;52:434-8.
25. Ivansson EL, Gustavsson IM, Wilander E, Magnusson PK, Gyllensten UB. Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical cancer in situ. Int J Cancer 2009;125:2930-5.
26. Michels KB, zur Hausen H. HPV vaccine for all. Lancet 2009;374:268-70.